Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer
Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer
复制标题
DOI：
10.1158/1055-9965.epi-05-0823
复制
发表时间：
2006-06-01
影响因子：
3.8
通讯作者：
Giles, Graham G.
中科院分区：
文献类型：
--
作者：
Severi, Gianluca;Morris, Howard A.;Giles, Graham G.
最近的一些流行病学研究未能证实早期研究中观察到的胰岛素样生长因子-I (IGF-I) 与前列腺癌风险之间存在正相关性，但报告了 IGF 结合蛋白-3 (IGFBP-3) 与前列腺癌风险之间存在正相关性的提示性证据，这一结果与早期认为高水平的 IGFBP-3 可预防前列腺癌的假设相矛盾。我们通过测量在一项 17,049 名男性参与的前瞻性队列研究中基线时收集的血浆样本中的两种肽来测试 IGF-I 和 IGFBP-3 与前列腺癌风险之间的关联。我们采用病例队列设计，包括平均 8.7 年随访期间诊断的 524 例病例和随机抽样的 1,826 名男性亚队列。使用针对出生国家和饮酒量进行调整的 Cox 模型测试了每种肽水平与前列腺癌风险之间的关联。前列腺癌的风险与 IGF-I 基线水平或 IGF-I/IGFBP-3 摩尔比无关（所有比值比在 0.82 至 1.08 之间；P 趋势 >= 0.2），而风险随着 IGFBP-3 基线水平的增加而增加（P 趋势 = 0.008）。与 IGFBP-3 浓度加倍相关的风险比 (HR) 为 1.70（95% 置信区间，1.15-2.52）。 IGFBP-3 的四分位数 4 相对于四分位数 1 的 HR 为 1.49（95% 置信区间，1.11-2.00）。 HR 不因肿瘤侵袭性或发病年龄而不同（所有 P >= 0.4）。在我们的研究中，高水平的 IGFBP-3 而不是 IGF-I 与前列腺癌风险增加相关。
Some recent epidemiologic studies have failed to confirm positive associations between insulin-like growth factor-I (IGF-I) and the risk of prostate cancer observed in earlier studies but have reported suggestive evidence for a positive association between IGF-binding protein-3 (IGFBP-3) and prostate cancer risk, a result contradicting the earlier assumption that high levels of IGFBP-3 would be protective against prostate cancer. We tested the association between IGF-I and IGFBP-3 and prostate cancer risk by measuring the two peptides in plasma samples collected at baseline in a prospective cohort study of 17,049 men. We used a case-cohort design, including 524 cases diagnosed during a mean of 8.7 years follow-up and a randomly sampled subcohort of 1,826 men. The association between each peptide level and prostate cancer risk was tested using Cox models adjusted for country of birth and alcohol consumption. The risk of prostate cancer was not associated with baseline levels of IGF-I or the molar ratio IGF-I/IGFBP-3 (all odds ratios are between 0.82 and 1.08; P-trend >= 0.2), whereas the risk increased with baseline levels of IGFBP-3 (P-trend = 0.008). the hazard ratio (HR) associated with a doubling of the concentration of IGFBP-3 being 1.70 (95% confidence interval, 1.15-2.52). The HR for quartile 4 relative to quartile 1 of IGFBP-3 was 1.49 (95% confidence interval, 1.11-2.00). The HRs did not differ by tumor aggressiveness or age at onset (all Ps >= 0.4). In our study, high levels of IGFBP-3 but not IGF-I were associated with an increased risk of prostate cancer.